Abstract
The aim of this study is to assess melanoma risk in rheumatoid arthritis (RA). A literature review was performed, retrieving observational studies over 1990–2010 that provided estimates of relative risk of melanoma associated with RA, compared to the general population. We generated standardized incidence ratio (SIR) estimates across all studies, first pooling the data and then performing a random-effects model to generate the SIRs. We retrieved 713 citations; after reviewing the titles and abstracts, 124 were further reviewed, and of these, 11 met our inclusion criteria for analysis. Pooling the data, there were a total of 601 melanomas that were observed over 1,351,061 patient-years of follow-up, or 4.4 cases per 10,000 years. The expected number of melanomas over this interval was 596.2 for a pooled SIR of 1.01 [95% confidence interval (CI), 0.93, 1.09]. Excluding the two patient groups that were known to be exposed to biologics, the SIR estimate was unchanged (1.01; 95 CI, 0.93, 1.10). Our random-effects model similarly indicated an SIR for melanoma of 0.95 [95% credible interval (CrI), 0.86, 1.03] overall and 0.95 (95% CrI, 0.86, 1.04) excluding the two patient groups that were known to be exposed to biologics. These results do not highlight an important increased risk for melanoma in RA patients over-all, compared to the general population. It is not clear whether the risk is different for patients specifically exposed to biologic agents, although data are relatively few. Further study, especially of RA patients with a past history of melanoma, is warranted.
Similar content being viewed by others
References
George E, Makov I, Smith A (1993) Conjugate likelihood distributions. Scand J Stat 20:147–156
Dixon WG, Watson KD, Lunt M, Mercer LK, Hyrich KL, Symmons DP, British Society For Rheumatology Biologics Register Control Centre Consortium, British Society for Rheumatology Biologics Register (2010) Influence of anti-tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: results from the British Society for Rheumatology Biologics Register. Arthritis Care Res (Hoboken) 62(6):755–763
Mellemkjaer L et al (1996) Rheumatoid arthritis and cancer risk. Eur J Cancer 32:1753–1757
Thomas E et al (2000) Risk of malignancy among patients with rheumatic conditions. Int J Cancer 88(3):497–502
Askling J et al (2005) Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists. Ann Rheum Dis 64:1421–1426
Setoguchi S et al (2006) Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis. Arthritis Rheum 54(9):2757–2764
Wolfe F, Michaud K (2007) Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study. Arthritis Rheum 56(9):2886–2895
Abasolo L et al (2008) Cancer in rheumatoid arthritis: occurrence, mortality, and associated factors in a South European population. Semin Arthritis Rheum 37(6):388–397
Hemminki K et al (2008) Cancer risk in hospitalized rheumatoid arthritis patients. Rheumatology 47(5):698–701
Buchbinder R et al (2008) Incidence of melanoma and other malignancies among rheumatoid arthritis patients treated with methotrexate. Arthritis Rheum 59(6):794–799
Parikh-Patel A et al (2009) Risk of cancer among rheumatoid arthritis patients in California. Cancer Causes Control 20(6):1001–1010
Chen YJ et al (2011) The risk of cancer in patients with rheumatoid arthritis: a nationwide cohort study in Taiwan. Arthritis Rheum 63:352–358
Gridley G, McLaughlin JK, Ekbom A, Klareskog L, Adami HO, Hacker DG, Hoover R, Fraumeni JF Jr (1993) Incidence of cancer among patients with rheumatoid arthritis. J Natl Cancer Inst 85(4):307–311
Eggermont AM, Ten Hagen TL (2003) Tumor necrosis factor-based isolated limb perfusion for soft tissue sarcoma and melanoma: ten years of successful antivascular therapy. Curr Oncol Rep 5:79–80
Mariette X et al (2011) Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis. Ann Rheum Dis 70:1895–1904
Sponsors and acknowledgments
Dr. Bernatsky is a recipient of career awards from the Fonds de recherche en santé du Québec (FRSQ) and is a Canadian Arthritis Network scholar. She is a recipient of support from the McGill University Health Centre Department of Medicine and Research Institute. Dr. Rahme is a research scholar funded by the FRSQ.
Disclosures
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Perkins, S., Cohen, M., Rahme, E. et al. Melanoma and rheumatoid arthritis (brief report). Clin Rheumatol 31, 1001–1003 (2012). https://doi.org/10.1007/s10067-011-1908-x
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-011-1908-x